サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179960

非アルコール性脂肪性肝炎の世界市場：薬剤タイプ別、用途タイプ別、流通タイプ別、地域別－規模と動向、COVID-19の影響と2027年までの予測

Global Non-Alcoholic Steatohepatitis Market: Analysis By Drug Type, By Application Type, By Distribution Type, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027
出版日: | 発行: Daedal Research | ページ情報: 英文 130 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
非アルコール性脂肪性肝炎の世界市場：薬剤タイプ別、用途タイプ別、流通タイプ別、地域別－規模と動向、COVID-19の影響と2027年までの予測
出版日: 2023年01月05日
発行: Daedal Research
ページ情報: 英文 130 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の非アルコール性脂肪性肝炎の市場規模は、2021年の16億5,000万米ドルから、2027年には150億4,000万米ドルに達し、2022年から2027年までの予測期間中にCAGRで約50%の成長が予測されています。医療インフラへの投資拡大、多価不飽和脂肪酸や果糖を含む加工食品の消費増加、新薬開発への注力、非侵襲的診断法の発売に取り組む企業の増加は、市場の成長を促進しています。

当レポートでは、世界の非アルコール性脂肪性肝炎市場について調査分析し、市場分析、市場力学、競合情勢など、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 イントロダクション

  • 非アルコール性脂肪性肝炎市場：概要
    • 非アルコール性脂肪性肝炎の定義
    • 非アルコール性脂肪性肝炎の原因
    • 非アルコール性脂肪肝疾患の進行
  • 非アルコール性脂肪性肝炎市場セグメンテーション：概要
    • 非アルコール性脂肪性肝炎市場セグメンテーション

第3章 世界市場分析

  • 世界の非アルコール性脂肪性肝炎市場：分析
    • 世界の非アルコール性脂肪性肝炎市場：概要
    • 世界の非アルコール性脂肪性肝炎市場：金額別
    • 世界の非アルコール性脂肪性肝炎市場：薬剤タイプ別（ビタミンE・ピオグリタゾン、オカリバ、エラフィブラノール、セロンセルチブ・セニクリビロック、その他）
    • 世界の非アルコール性脂肪性肝炎市場：用途タイプ別（治療、診断）
    • 世界の非アルコール性脂肪性肝炎市場：流通タイプ別（小売薬局、病院薬局、オンライン薬局）
    • 世界の非アルコール性脂肪性肝炎市場：地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東およびアフリカ）
  • 世界の非アルコール性脂肪性肝炎市場：薬剤タイプ分析
    • 世界の非アルコール性脂肪性肝炎市場：概要：薬剤タイプ別
    • 世界のビタミンE・ピオグリタゾン非アルコール性脂肪性肝炎市場：金額別
    • 世界のエラフィブラノール非アルコール性脂肪性肝炎市場：金額別
    • 世界のオカリバ非アルコール性脂肪性肝炎市場：金額別
    • 世界のセロンセルチブ・セニクリビロック非アルコール性脂肪性肝炎市場：金額別
    • 世界のその他非アルコール性脂肪性肝炎市場：金額別
  • 世界の非アルコール性脂肪性肝炎市場：用途タイプ分析
    • 世界の非アルコール性脂肪性肝炎市場：概要：用途タイプ別
    • 世界の非アルコール性脂肪性肝炎治療市場：金額別
    • 世界の非アルコール性脂肪性肝炎診断市場：金額別
  • 世界の非アルコール性脂肪性肝炎市場：分布タイプ分析
    • 世界の非アルコール性脂肪性肝炎市場：概要：分布タイプ別
    • 世界の小売薬局非アルコール性脂肪性肝炎市場：金額別
    • 世界の病院薬局非アルコール性脂肪性肝炎市場：金額別
    • 世界のオンライン薬局非アルコール性脂肪性肝炎市場：金額別

第4章 地域市場分析

  • 北米の非アルコール性脂肪性肝炎市場：分析
  • アジア太平洋地域の非アルコール性脂肪性肝炎市場：分析
  • 欧州の非アルコール性脂肪性肝炎市場：分析
  • ラテンアメリカの非アルコール性脂肪性肝炎市場：分析
  • 中東およびアフリカの非アルコール性脂肪性肝炎市場：分析

第5章 COVID-19の影響

  • 世界の非アルコール性脂肪性肝炎市場に対するCOVID-19の影響
  • 世界の非アルコール性脂肪性肝炎市場に対するポストCOVID-19の影響

第6章 市場力学

  • 促進要因
    • 非アルコール性脂肪性肝炎の有病率の上昇
    • 関連する慢性疾患の増加例
    • 座りがちなライフスタイルの採用の増加
    • 健康意識の高まり
    • 都市化
  • 課題
    • 低コストで確実な診断方法の欠如
    • 規制コンプライアンス
  • 市場動向
    • 人工知能（AI）の統合の増加
    • デジタル化
    • パイプライン医薬品のプロモーションの強化
    • 研究開発への投資の増加

第7章 競合情勢

  • 世界の非アルコール性脂肪性肝炎市場の企業：薬剤開発別

第8章 企業プロファイル

  • Intercept Pharmaceuticals, Inc.
  • Novartis AG
  • Siemens Healthineers AG
  • AstraZeneca PLC
  • Galectin Therapeutics Inc.
  • GENFIT S.A.
  • Madrigal Pharmaceuticals, Inc.
  • Inventiva S.A.
  • ONE WAY LIVER, S.L. (OWL)
  • Galmed Pharmaceuticals Ltd.
  • Prometheus Laboratories Inc.
  • BioPredictive
  • Cirius Therapeutics
図表

List of Tables

  • Table 1: Global Non-Alcoholic Steatohepatitis Market Players by Drug Development

List of Figures

  • Figure 1: Causes of Non-Alcoholic Steatohepatitis (NASH)
  • Figure 2: Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
  • Figure 3: Non-Alcoholic Steatohepatitis Market (NASH) Segmentation
  • Figure 4: Global Non-Alcoholic Steatohepatitis Market by Value; 2017-2021 (US$ Billion)
  • Figure 5: Global Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
  • Figure 6: Global Non-Alcoholic Steatohepatitis Market by Drug Type; 2021 and 2027 (Percentage, %)
  • Figure 7: Global Non-Alcoholic Steatohepatitis Market by Application Type; 2021 (Percentage, %)
  • Figure 8: Global Non-Alcoholic Steatohepatitis Market by Distribution Type; 2021 (Percentage, %)
  • Figure 9: Global Non-Alcoholic Steatohepatitis Market by Region; 2021 (Percentage, %)
  • Figure 10: Global Vitamin E and Pioglitazone Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Billion)
  • Figure 11: Global Elafibranor Non-Alcoholic Steatohepatitis Market by Value; 2023-2027 (US$ Billion)
  • Figure 12: Global Ocaliva Non-Alcoholic Steatohepatitis Market by Value; 2023-2027 (US$ Billion)
  • Figure 13: Global Selonsertib & Cenicriviroc Non-Alcoholic Steatohepatitis Market by Value; 2024-2027 (US$ Million)
  • Figure 14: Global Others Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Billion)
  • Figure 15: Global Non-Alcoholic Steatohepatitis Treatment Market by Value; 2017-2021 (US$ Billion)
  • Figure 16: Global Non-Alcoholic Steatohepatitis Treatment Market by Value; 2022-2027 (US$ Billion)
  • Figure 17: Global Non-Alcoholic Steatohepatitis Diagnosis Market by Value; 2017-2021 (US$ Million)
  • Figure 18: Global Non-Alcoholic Steatohepatitis Diagnosis Market by Value; 2022-2027 (US$ Million)
  • Figure 19: Global Retail Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2017-2021 (US$ Million)
  • Figure 20: Global Retail Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
  • Figure 21: Global Hospital Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2017-2021 (US$ Million)
  • Figure 22: Global Hospital Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
  • Figure 23: Global Online Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2017-2021 (US$ Million)
  • Figure 24: Global Online Pharmacies Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Million)
  • Figure 25: North America Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
  • Figure 26: North America Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
  • Figure 27: North America Non-Alcoholic Steatohepatitis Market by Region; 2021 (Percentage, %)

Figure 28:The US Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Billion)

  • Figure 29: Canada Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 30: Mexico Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 31: Asia Pacific Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
  • Figure 32: Asia Pacific Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Million)
  • Figure 33: Asia Pacific Non-Alcoholic Steatohepatitis Market by Region; 2021 (Percentage, %)
  • Figure 34: China Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 35: Japan Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 36: India Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 37: Australia Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 38: South Korea Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 39: Rest of Asia Pacific Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 40: Europe Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
  • Figure 41: Europe Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Billion)
  • Figure 42: Europe Non-Alcoholic Steatohepatitis Market by Region; 2021 (Percentage, %)
  • Figure 43: Germany Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 44: UK Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 45: France Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 46: Italy Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 47: Spain Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 48: Rest of Europe Non-Alcoholic Steatohepatitis Market by Value; 2021-2027 (US$ Million)
  • Figure 49: Latin America Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
  • Figure 50: Latin America Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Million)
  • Figure 51: Middle East and Africa Non-Alcoholic Steatohepatitis Market by value; 2017-2021 (US$ Million)
  • Figure 52: Middle East and Africa Non-Alcoholic Steatohepatitis Market by Value; 2022-2027 (US$ Million)
  • Figure 53: NASH Prevalence, Diagnosed and Treated Cases; 2021 & 2030 (Million)
  • Figure 54: Global Number of People with Diabetes; 2021-2027 (Million)
  • Figure 55: Global Number of People with Obesity; 2020-2030 (Million)
  • Figure 56: Global Artificial Intelligence Market Size; 2021-2025 (US$ Billion)
  • Figure 57: Intercept Pharmaceuticals, Inc. Net Product Revenue by Geographical Region; 2021 (Percentage, %)
  • Figure 58: Novartis AG Net Sales by Reportable Segments; 2021 (Percentage, %)
  • Figure 59: Siemens Healthineers AG Revenue by Segments; 2022 (Percentage, %)
  • Figure 60: AstraZeneca PLC Revenue by Geographical Region; 2021 (Percentage, %)
目次

The global non-alcoholic steatohepatitis (NASH) market was valued at US$1.65 billion in 2021. The market value is projected to grow to US$15.04 billion by 2027. Non-Alcoholic Steatohepatitis (NASH) is an inflammatory liver disease associated with excessive fat accumulation in the liver (steatosis), hepatocellular ballooning, and inflammation. Non-Alcoholic Steatohepatitis or "Silent Liver Disease" leads to scarring of the liver, a kind of liver disorder caused by long-term abuse of alcohol but mainly develops in patients who are non-alcoholic or consume very little alcohol. Non-Alcoholic steatohepatitis (NASH) is the second stage of non-alcoholic fatty liver disease (NAFLD) that has progressed to the point of liver inflammation and cell damage.

The factors such as increased investment in medical infrastructure, rising consumption of processed foods containing polyunsaturated fatty acids & fructose, increased focus on development of new drugs and many companies engaged in the launch of non-invasive diagnostic procedures, are expected to drive the overall market growth in the forecasted period. The market is anticipated to grow at a CAGR of approx. 50% during the forecasted period of 2022-2027.

Market Segmentation Analysis:

By Drug Type: The report provides the bifurcation of the market into five segments based on the drug type: vitamin e & pioglitazone, ocaliva, elafibranor, selonsertib & cenicriviroc and others. In 2021, the vitamin E & pioglitazone segment held the major share of the global non-alcoholic steatohepatitis market as these two drugs are seen to be effective in improving the condition associated with NASH and with no FDA approved drugs in the market to treat NASH, these drugs are expected to be continuously demanded and recommended by medical professionals as the first line drugs for treating NASH. Elafibranor non-alcoholic steatohepatitis market is the fastest growing segment of global non-alcoholic steatohepatitis market in the forecasted period of 2023-2027 owing to positive impact of elafibranor in NASH treatment during clinical trials and drug's capability to reduce fat substance of liver, improving the conditions caused by NASH.

By Application Type: The report provides the bifurcation of the market into two segments based on application type: treatment and diagnosis. The non-alcoholic steatohepatitis (NASH) treatment market is both the largest and fastest growing segment of global non-alcoholic steatohepatitis (NASH) market owing to increased prevalence of NASH, expected launch of new pipeline drugs by pharmaceutical companies and development of various potential pathways for NASH treatments, including lipogenesis inhibitors, medications targeting the farnesoid X receptor axis, ASK1 inhibitors, etc.

By Distribution Type: The report provides the bifurcation of the market into three segments based on distribution type: retail pharmacies, online pharmacies and hospital pharmacies. Retail pharmacies non-alcoholic steatohepatitis (NASH) market is the largest and fastest segment of global non-alcoholic steatohepatitis (NASH) market owing to strong presence of drug stores & retail pharmacies, more engaging patient centric services, easy accessibility in terms of more convenient locations and better drug portfolio with more thorough information about medications and health items that can be used to treat the conditions associated with NASH.

By Region: The report provides insight into the non-alcoholic steatohepatitis (NASH) market based on the regions namely North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The North America non-alcoholic steatohepatitis market holds the largest share in global non-alcoholic steatohepatitis market owing to the rise in number of cases of associated chronic diseases like obesity, increasing healthcare expenditure and presence of major NASH players in the region.

Whereas, Asia Pacific non-alcoholic steatohepatitis market in expected to be the fastest growing segment of global NASH market owing to growing prevalence of NASH, advancing healthcare infrastructure and increasing investments from international NASH players in countries like China and India, having positive impact on diagnostic advancements in the region. The Asia Pacific non-alcoholic steatohepatitis market is further divided into six regions on the basis of geographical operations, namely, China, India, Japan, Australia, South Korea and Rest of Asia Pacific, where China non-alcoholic steatohepatitis market held the largest share in Asia Pacific non-alcoholic steatohepatitis market.

Market Dynamics:

Growth Drivers: The global non-alcoholic steatohepatitis market has been growing over the past few years, due to factors such as rising prevalence of non-alcoholic steatohepatitis, rising cases of associated chronic diseases, increasing adoption of sedentary lifestyle, growing health awareness etc. NASH is a chronic inflammatory liver disease and if left untreated, can progress to cirrhosis and liver cancer. In addition to having an increased risk for liver-related illness, people with NASH also tend to have a higher risk of suffering from a heart attack or stroke due to the presence of other comorbidities (when there are two or more medical conditions present) such as high blood pressure and coronary artery disease. So, with rising number of people suffering from NASH, there is an increasing demand for non-alcoholic steatohepatitis (NASH) therapeutics, boosting the growth of global non-alcoholic steatohepatitis market.

Challenges: However, the market growth would be negatively impacted by various challenges such as absence of low cost & definitive diagnostic methods, regulatory compliance etc. NASH is presently diagnosed using methods such as blood test, imaging or liver biopsy which are time consuming, inefficient and cumbersome diagnostic procedures. Liver biopsy is an invasive method associated with high cost, sampling errors and major risks like bleeding, pain, perforation, infection and even (on occasion) death, resulting in many patients opting out of diagnosis and hence leading to low diagnosis rate of NASH, impeding the growth of global non-alcoholic steatohepatitis market.

Trends: The market is projected to grow at a fast pace during the forecasted period, due to various latest trends such as integration of artificial intelligence (AI), digitaization, increased promotion of pipeline drugs, etc. Rising trend of digitalization has allowed various companies and organizations to better advertise company's recent development about existing and upcoming drugs that are currently available in the market and reach wider consumer base in terms of spreading more awareness about the prevalence of NASH using various social media platforms, boosting the growth of the global NASH market.

Impact Analysis of COVID-19 and Way Forward:

COVID-19 brought in many changes in the world in terms of reduced productivity, loss of life, business closures, closing down of factories and organizations, and shift to an online mode of work. With lockdown polices imposed by the government to prevent the spead of virus, there was an increased adoption of sedentary lifestyle, rise in consumption of processed food containing polyunsaturated fatty acids, decreased regular exercises and increased consumption of fructose-rich diets, risk factors assosiated with increased likelihood of developing NASH. COVID-19 pandemic also contributed towards a rise in cardiovascular & metabolic risk factors along with appearance of new chronic pathologies, increasing the risk of developing NAFLD and NASH, having a positive effect on the market in terms of increased demand for current treatment practices, diagnostic tools and emerging drugs for the treatment of NASH. Therefore, the global impact of COVID-19 on non-alcoholic steatohepatitis market turned out to be positive.

Competitive Landscape:

The market for non-alcoholic steatohepatitis has been consolidated. The key players of non-alcoholic steatohepatitis market are:

Intercept Pharmaceuticals, Inc.

Novartis AG

Siemens Healthineers AG

AstraZeneca PLC

Galectin Therapeutics Inc.

GENFIT S.A.

Madrigal Pharmaceuticals, Inc.

Inventiva S.A.

ONE WAY LIVER, S.L.

Galmed Pharmaceuticals Ltd.

Cirius Therapeutics

Prometheus Laboratories Inc.

BioPredictive

Currently, there are no approved drugs for the treatment of non-alcoholic steatohepatitis (NASH) and therefore several companies are adopting organic and inorganic strategies to develop novel drugs like product launches, approvals, mergers and acquisitions. For instance, On May 27, 2021, ONE WAY LIVER, S.L. (OWL) announced that the company entered into an agreement with Sagimet Biosciences to use OWL's Metabolomics Technology in Sagimet´s TVB-2640 Phase 2b Clinical NASH Trial FASCINATE-2.

Table of Contents

    1. Executive Summary

    2. Introduction

    • 2.1 Non-Alcoholic Steatohepatitis Market: An Overview
      • 2.1.1 Definition of Non-Alcoholic Steatohepatitis (NASH)
      • 2.1.2 Causes of Non-Alcoholic Steatohepatitis (NASH)
      • 2.1.3 Progression of Non-Alcoholic fatty liver disease (NAFLD)
    • 2.2 Non-Alcoholic Steatohepatitis Market (NASH) Segmentation: An Overview
      • 2.2.1 Non-Alcoholic Steatohepatitis Market (NASH) Segmentation

    3. Global Market Analysis

    • 3.1 Global Non-Alcoholic Steatohepatitis Market: An Analysis
      • 3.1.1 Global Non-Alcoholic Steatohepatitis Market: An Overview
      • 3.1.2 Global Non-Alcoholic Steatohepatitis Market by Value
      • 3.1.3 Global Non-Alcoholic Steatohepatitis Market by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc and Others)
      • 3.1.4 Global Non-Alcoholic Steatohepatitis Market by Application Type (Treatment and Diagnosis)
      • 3.1.5 Global Non-Alcoholic Steatohepatitis Market by Distribution Type (Retail Pharmacies, Hospital Pharmacies and Online Pharmacies)
      • 3.1.6 Global Non-Alcoholic Steatohepatitis Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
    • 3.2 Global Non-Alcoholic Steatohepatitis Market: Drug Type Analysis
      • 3.2.1 Global Non-Alcoholic Steatohepatitis Market by Drug Type: An Overview
      • 3.2.2 Global Vitamin E and Pioglitazone Non-Alcoholic Steatohepatitis Market by Value
      • 3.2.3 Global Elafibranor Non-Alcoholic Steatohepatitis Market by Value
      • 3.2.4 Global Ocaliva Non-Alcoholic Steatohepatitis Market by Value
      • 3.2.5 Global Selonsertib & Cenicriviroc Non-Alcoholic Steatohepatitis Market by Value
      • 3.2.6 Global Others Non-Alcoholic Steatohepatitis Market by Value
    • 3.3 Global Non-Alcoholic Steatohepatitis Market: Application Type Analysis
      • 3.3.1 Global Non-Alcoholic Steatohepatitis Market by Application Type: An Overview
      • 3.3.2 Global Non-Alcoholic Steatohepatitis Treatment Market by Value
      • 3.3.3 Global Non-Alcoholic Steatohepatitis Diagnosis Market by Value
    • 3.4 Global Non-Alcoholic Steatohepatitis Market: Distribution Type Analysis
      • 3.4.1 Global Non-Alcoholic Steatohepatitis Market by Distribution Type: An Overview
      • 3.4.2 Global Retail Pharmacies Non-Alcoholic Steatohepatitis Market by Value
      • 3.4.3 Global Hospital Pharmacies Non-Alcoholic Steatohepatitis Market by Value
      • 3.4.4 Global Online Pharmacies Non-Alcoholic Steatohepatitis Market by Value

    4. Regional Market Analysis

    • 4.1 North America Non-Alcoholic Steatohepatitis Market: An Analysis
      • 4.1.1 North America Non-Alcoholic Steatohepatitis Market: An Overview
      • 4.1.2 North America Non-Alcoholic Steatohepatitis Market by Value
      • 4.1.3 North America Non-Alcoholic Steatohepatitis Market by Region (The US, Canada and Mexico)
      • 4.1.4 The US Non-Alcoholic Steatohepatitis Market by Value
      • 4.1.5 Canada Non-Alcoholic Steatohepatitis Market by Value
      • 4.1.6 Mexico Non-Alcoholic Steatohepatitis Market by Value
    • 4.2 Asia Pacific Non-Alcoholic Steatohepatitis Market: An Analysis
      • 4.2.1 Asia Pacific Non-Alcoholic Steatohepatitis Market: An Overview
      • 4.2.2 Asia Pacific Non-Alcoholic Steatohepatitis Market by Value
      • 4.2.3 Asia Pacific Non-Alcoholic Steatohepatitis Market by Region (China, Japan, India, Australia, South Korea and Rest of Asia Pacific)
      • 4.2.4 China Non-Alcoholic Steatohepatitis Market by Value
      • 4.2.5 Japan Non-Alcoholic Steatohepatitis Market by Value
      • 4.2.6 India Non-Alcoholic Steatohepatitis Market by Value
      • 4.2.7 Australia Non-Alcoholic Steatohepatitis Market by Value
      • 4.2.8 South Korea Non-Alcoholic Steatohepatitis Market by Value
      • 4.2.9 Rest of Asia Pacific Non-Alcoholic Steatohepatitis Market by Value
    • 4.3 Europe Non-Alcoholic Steatohepatitis Market: An Analysis
      • 4.3.1 Europe Non-Alcoholic Steatohepatitis Market: An Overview
      • 4.3.2 Europe Non-Alcoholic Steatohepatitis Market by Value
      • 4.3.3 Europe Non-Alcoholic Steatohepatitis Market by Region (Germany, UK, France, Italy, Spain and Rest of Europe)
      • 4.3.4 Germany Non-Alcoholic Steatohepatitis Market by Value
      • 4.3.5 UK Non-Alcoholic Steatohepatitis Market by Value
      • 4.3.6 France Non-Alcoholic Steatohepatitis Market by Value
      • 4.3.7 Italy Non-Alcoholic Steatohepatitis Market by Value
      • 4.3.8 Spain Non-Alcoholic Steatohepatitis Market by Value
      • 4.3.9 Rest of Europe Non-Alcoholic Steatohepatitis Market by Value
    • 4.4 Latin America Non-Alcoholic Steatohepatitis Market: An Analysis
      • 4.4.1 Latin America Non-Alcoholic Steatohepatitis Market: An Overview
      • 4.4.2 Latin America Non-Alcoholic Steatohepatitis Market by Value
    • 4.5 Middle East and Africa Non-Alcoholic Steatohepatitis Market: An Analysis
      • 4.5.1 Middle East and Africa Non-Alcoholic Steatohepatitis Market: An Overview
      • 4.5.2 Middle East and Africa Non-Alcoholic Steatohepatitis Market by Value

    5. Impact of COVID-19

    • 5.1 Impact of COVID-19 on Non-Alcoholic Steatohepatitis (NASH) Market
    • 5.2 Post COVID-19 Impact on Non-Alcoholic Steatohepatitis (NASH) Market

    6. Market Dynamics

    • 6.1 Growth Driver
      • 6.1.1 Rising prevalence of Non-Alcoholic Steatohepatitis (NASH)
      • 6.1.2 Rising Cases of Associated Chronic Diseases
      • 6.1.3 Rising adoption of Sedentary Lifestyle
      • 6.1.4 Rising Health Awareness
      • 6.1.5 Urbanization
    • 6.2 Challenges
      • 6.2.1 Absence of Low Cost and Definitive Diagnostic Methods
      • 6.2.2 Regulatory Compliance
    • 6.3 Market Trends
      • 6.3.1 Increasing Integration of Artificial Intelligence (AI)
      • 6.3.2 Digitalization
      • 6.3.3 Increased Promotion of Pipeline Drugs
      • 6.3.4 Increasing Investment on Research and Development (R&D)

    7. Competitive Landscape

    • 7.1 Global Non-Alcoholic Steatohepatitis Market Players by Drug Development

    8. Company Profiles

    • 8.1 Intercept Pharmaceuticals, Inc.
      • 8.1.1 Business Overview
      • 8.1.2 Operating Geographical Region
      • 8.1.3 Business Strategy
    • 8.2 Novartis AG
      • 8.2.1 Business Overview
      • 8.2.2 Operating Segment
      • 8.2.3 Business Strategy
    • 8.3 Siemens Healthineers AG
      • 8.3.1 Business Overview
      • 8.3.2 Operating Segments
      • 8.3.3 Business Strategy
    • 8.4 AstraZeneca PLC
      • 8.4.1 Business Overview
      • 8.4.2 Operating Geographical Region
      • 8.4.3 Business Strategy
    • 8.5 Galectin Therapeutics Inc.
      • 8.5.1 Business Overview
      • 8.5.2 Business Strategy
    • 8.6 GENFIT S.A.
      • 8.6.1 Business Overview
      • 8.6.2 Business Strategy
    • 8.7 Madrigal Pharmaceuticals, Inc.
      • 8.7.1 Business Overview
      • 8.7.2 Business Strategy
    • 8.8 Inventiva S.A.
      • 8.8.1 Business Overview
      • 8.8.2 Business Strategy
    • 8.9 ONE WAY LIVER, S.L. (OWL)
      • 8.9.1 Business Overview
      • 8.9.2 Business Strategy
    • 8.10 Galmed Pharmaceuticals Ltd.
      • 8.10.1 Business Overview
      • 8.10.2 Business Strategy
    • 8.11 Prometheus Laboratories Inc.
      • 8.11.1 Business Overview
      • 8.11.2 Business Strategies
    • 8.12 BioPredictive
      • 8.12.1 Business Overview
    • 8.13 Cirius Therapeutics
      • 8.13.1 Business Overview